Verastem, Inc. (VSTM) $2.22 am.27.4.20 (Seite 4)
eröffnet am 28.04.20 09:37:30 von
neuester Beitrag 23.02.24 17:56:24 von
neuester Beitrag 23.02.24 17:56:24 von
Beiträge: 101
ID: 1.323.971
ID: 1.323.971
Aufrufe heute: 0
Gesamt: 10.662
Gesamt: 10.662
Aktive User: 0
ISIN: US92337C1045 · WKN: A1JTPU · Symbol: VSTM
1,0200
USD
0,00 %
0,0000 USD
Letzter Kurs 01.06.23 Nasdaq
Neuigkeiten
18.04.24 · Business Wire (engl.) |
04.04.24 · Business Wire (engl.) |
18.03.24 · Business Wire (engl.) |
14.03.24 · Business Wire (engl.) |
11.03.24 · Business Wire (engl.) |
Werte aus der Branche Biotechnologie
Wertpapier | Kurs | Perf. % |
---|---|---|
1,9000 | +59,66 | |
0,5922 | +44,44 | |
7,3500 | +43,84 | |
11,690 | +40,84 | |
0,7000 | +36,69 |
Wertpapier | Kurs | Perf. % |
---|---|---|
10,110 | -13,44 | |
8,2200 | -13,47 | |
7,6100 | -17,20 | |
1,6100 | -18,27 | |
2,1200 | -21,77 |
Beitrag zu dieser Diskussion schreiben
Auch einer der vielen " beaten down bio stocks " bin rein hoffe auf gute news und Turnaround der Biotechs.
S.
S.
Nach dem Ausstieg von Highbridge (endlich) und dem Kursrückgang von USD 4.93 (52w High) auf gegen USD 2.50 hat sich der Kurs seitdem wieder über USD 3.00 bewegt.
Spannend könnte werden:
Duvelisib to Combat COVID-19
https://clinicaltrials.gov/ct2/show/NCT04372602
Estimated Primary Completion Date: November 30, 2021
Spannend könnte werden:
Duvelisib to Combat COVID-19
https://clinicaltrials.gov/ct2/show/NCT04372602
Estimated Primary Completion Date: November 30, 2021
Zwei positive News aber der Kurs bröckelt ab... ATM?
Verastem Oncology and Amgen Partner to Evaluate VS-6766 in Combination with LUMAKRASTM (Sotorasib) in Patients with KRAS G12C-Mutant Non-Small Cell Lung Cancer
Clinical Collaboration Will Assess Safety and Efficacy of More Complete Vertical Blockade Along RAS Pathway
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced a clinical collaboration agreement with Amgen to evaluate the combination of VS-6766, Verastem Oncology's investigational dual RAF/MEK inhibitor, with Amgen's KRAS G12C inhibitor LUMAKRASTM (sotorasib) in KRAS G12C-mutant non-small cell lung cancer (NSCLC).
The Phase 1/2 trial will evaluate the safety, tolerability and efficacy of VS-6766 in combination with LUMAKRASTM in patients with KRAS G12C-mutant NSCLC who have not been previously treated with a KRAS G12C inhibitor as well as in patients who have progressed on a KRAS G12C inhibitor. The study will therefore investigate the potential benefits of a more complete vertical blockade of the RAS pathway with the combination of VS-6766 (RAF/MEK blockade) with LUMAKRASTM (G12C inhibition) in KRAS G12C-mutant locally advanced or metastatic NSCLC.
"Recent data indicate that acquired resistance to KRAS G12C inhibitors in patients occurs predominantly through additional mutations in the RAS pathway, many of which may be addressed with a downstream inhibitor such as VS-6766,"1 said Ramaswamy Govindan, M.D., Professor, Department of Medicine, Oncology Division at Washington University School of Medicine and lead investigator of the study. "This clinical study of VS-6766 and LUMAKRASTM will build on preclinical data showing synergy between these two agents, including tumor regression through deeper blockade of ERK pathway signaling."2
"We are pleased to partner with Amgen on this important research that could potentially expand treatment options for patients with KRAS G12C-mutant NSCLC," said Brian Stuglik, CEO of Verastem Oncology. "This collaboration advances our strategy to fully explore the potential of VS-6766 as a backbone of therapy to treat RAS pathway-driven cancers."
Verastem Oncology expects to initiate the clinical trial with VS-6766 and LUMAKRASTM by the end of 2021.
https://newsfilter.io/articles/verastem-oncology-and-amgen-p…
Clinical Collaboration Will Assess Safety and Efficacy of More Complete Vertical Blockade Along RAS Pathway
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced a clinical collaboration agreement with Amgen to evaluate the combination of VS-6766, Verastem Oncology's investigational dual RAF/MEK inhibitor, with Amgen's KRAS G12C inhibitor LUMAKRASTM (sotorasib) in KRAS G12C-mutant non-small cell lung cancer (NSCLC).
The Phase 1/2 trial will evaluate the safety, tolerability and efficacy of VS-6766 in combination with LUMAKRASTM in patients with KRAS G12C-mutant NSCLC who have not been previously treated with a KRAS G12C inhibitor as well as in patients who have progressed on a KRAS G12C inhibitor. The study will therefore investigate the potential benefits of a more complete vertical blockade of the RAS pathway with the combination of VS-6766 (RAF/MEK blockade) with LUMAKRASTM (G12C inhibition) in KRAS G12C-mutant locally advanced or metastatic NSCLC.
"Recent data indicate that acquired resistance to KRAS G12C inhibitors in patients occurs predominantly through additional mutations in the RAS pathway, many of which may be addressed with a downstream inhibitor such as VS-6766,"1 said Ramaswamy Govindan, M.D., Professor, Department of Medicine, Oncology Division at Washington University School of Medicine and lead investigator of the study. "This clinical study of VS-6766 and LUMAKRASTM will build on preclinical data showing synergy between these two agents, including tumor regression through deeper blockade of ERK pathway signaling."2
"We are pleased to partner with Amgen on this important research that could potentially expand treatment options for patients with KRAS G12C-mutant NSCLC," said Brian Stuglik, CEO of Verastem Oncology. "This collaboration advances our strategy to fully explore the potential of VS-6766 as a backbone of therapy to treat RAS pathway-driven cancers."
Verastem Oncology expects to initiate the clinical trial with VS-6766 and LUMAKRASTM by the end of 2021.
https://newsfilter.io/articles/verastem-oncology-and-amgen-p…
Alliance Global Partners initiates coverage on Verastem with a Buy rating and announces Price Target of $6.
https://quantisnow.com/insight/1217075?s=s
https://quantisnow.com/insight/1217075?s=s
Antwort auf Beitrag Nr.: 68.286.368 von bernie55 am 24.05.21 13:47:47Verastem Oncology to Present at the 2021 Jefferies Virtual Healthcare Conference
May 25, 2021 07:00 AM Eastern Daylight Time
BOSTON--( BUSINESS WIRE )--Verastem, Inc. (Nasdaq: VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will present at the 2021 Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:00 p.m. ET.
A live webcast of the presentation will be available on the investors section of the Company’s website at www.verastem.com .
An archived presentation will be available for 30 days.
https://flashalert.me/?symbol=VSTM&source=PR&referer=https:/…
May 25, 2021 07:00 AM Eastern Daylight Time
BOSTON--( BUSINESS WIRE )--Verastem, Inc. (Nasdaq: VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will present at the 2021 Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:00 p.m. ET.
A live webcast of the presentation will be available on the investors section of the Company’s website at www.verastem.com .
An archived presentation will be available for 30 days.
https://flashalert.me/?symbol=VSTM&source=PR&referer=https:/…
Das klingt gut, sogar sehr gut.
Der Kurs reagiert:
🎵
Der Kurs reagiert:
🎵
Antwort auf Beitrag Nr.: 64.659.289 von richdotcom am 05.08.20 20:25:48
Da sieht man mal, dass ich "keine Ahnung" habe.....zumindest laut paar "Profis" aus verschiedenen Foren....
Erstes Ziel erreicht - meine Leser freut's :-)
Zitat von richdotcom: Guten Abend!
Entgegen vieler Luftblasen im Biotechsektor und zeitweise künstlich geschaffenen Kursschüben, haben wir es hier mit einer Riesenchance zu tun. Das Unternehmen arbeitet sehr fokussiert und zielstrebig an einer Revolution auf dem Markt der Krebsbekämpfung. Verastems führender Krebs-Hemmer Defactinib wurde zur Behandlung von chronischer lymphatischer Leukämie zugelassen. Der Wirkstoff kommt aber auch für den Einsatz gegen Bauchspeicheldrüsenkrebs, Eierstockkrebs und Lungenkrebs in Frage. Der neue Ansatz der Entwicklung neuer Medikamente, die gezielt
an Punkten wirken, die von Krebsstammzellen genutzt werden, ist einzigartig. Dieser Ansatz, der in Ärztekongressen als vielversprechend angesehen wird, hat Milliardenpotential. Die FDA
hat aktuell auch die Zulassung für ein beschleunigtes Verfahren zur Behandlung von T-Zell-Lymphomen erteilt. Allein in Deutschland erkranken hier knapp 1000 Menschen jährlich. Das Medikament hat den großen Vorteil, dass es oral verabreicht werden kann, somit müssen immungeschwächte Patienten nicht gesondert in diesen Zeiten Ärztepraxen oder Kliniken aufsuchen. Vor wenigen Tagen startete Verastem eine neue Studie mit dem Ziel, ein Medikament gegen das Aderhautmelanom, einem bösartigen Tumor im Auge, zu bekämpfen. Die ersten Datenauswertungen werden gegen Ende des letzten Quartals erwartet. Zwei weitere große Pluspunkte sind das Vertriebsnetz mit Chugai, einem Tochterunternehmen der Schweizer Roche, und damit verbundenen Niederlassungen in den USA, Deutschland, Frankreich, Großbritannien, Taiwan mit China und die Kooperationen mit Pfizer, Merck und Sanofi. Mit letzterer Partnerschaft spielen sie auch indirekt in der Thematik Covid-19 mit. Prognosen sind immer gefährlich, aber gemessen den Chancen im Marktpotential und einer möglichen Übernahme wirkt der Kurs wie ein Schnäppchen. Ein Erreichen der Kurse vor wenigen Jahren alleine würde 400% ausmachen. Langfristig kann diese Aktie einen ähnlichen Weg gehen wie Novavax.
Nur meine Meinung. Handelsvolumen nimmt zu!
Viel Erfolg bei all Euren Investitionen!
Da sieht man mal, dass ich "keine Ahnung" habe.....zumindest laut paar "Profis" aus verschiedenen Foren....
Antwort auf Beitrag Nr.: 68.286.368 von bernie55 am 24.05.21 13:47:47Verastem upgraded at BTIG; says FDA designation validates development approach
- BTIG analyst Robert "Bert" Hazlett has upgraded the stock to buy from neutral and the price target of $8.00 per share implies a premium of ~344.4% to the last close.
- VS-6766 is Verastem’s investigational RAF/MEK inhibitor, and defactinib is its FAK inhibitor, and the combination is currently undergoing the investigator-initiated Phase 1/2 FRAME trial where topline data indicated 52% of overall response rate (ORR) in a cohort of patients (n=24).
- In patients with KRAS Mutant Tumors and KRAS Wild-Type Tumors, the ORR stood at 70% and 44%, respectively.
- “With this early but meaningful regulatory validation de-risking the program, we upgrade VSTM shares to Buy," the analyst wrote citing the synergistic activity of both molecules, particularly in KRAS-mutant tumors.
https://newsfilter.io/a/06ef4174df2e5a252796803b280e8b0d
- BTIG analyst Robert "Bert" Hazlett has upgraded the stock to buy from neutral and the price target of $8.00 per share implies a premium of ~344.4% to the last close.
- VS-6766 is Verastem’s investigational RAF/MEK inhibitor, and defactinib is its FAK inhibitor, and the combination is currently undergoing the investigator-initiated Phase 1/2 FRAME trial where topline data indicated 52% of overall response rate (ORR) in a cohort of patients (n=24).
- In patients with KRAS Mutant Tumors and KRAS Wild-Type Tumors, the ORR stood at 70% and 44%, respectively.
- “With this early but meaningful regulatory validation de-risking the program, we upgrade VSTM shares to Buy," the analyst wrote citing the synergistic activity of both molecules, particularly in KRAS-mutant tumors.
https://newsfilter.io/a/06ef4174df2e5a252796803b280e8b0d
Sehr schön, gut dass ich geduldig geblieben bin.
18.04.24 · Business Wire (engl.) · Verastem |
04.04.24 · Business Wire (engl.) · Verastem |
18.03.24 · Business Wire (engl.) · Verastem |
14.03.24 · Business Wire (engl.) · Verastem |
11.03.24 · Business Wire (engl.) · Verastem |
05.03.24 · Business Wire (engl.) · Verastem |
05.03.24 · Business Wire (engl.) · Verastem |
29.01.24 · Business Wire (engl.) · Verastem |
18.01.24 · Business Wire (engl.) · Verastem |
11.01.24 · Business Wire (engl.) · Verastem |